Skye Bioscience

SAN DIEGO, CA · Founded 2011 · Biotech · Public

Proprietary cannabinoid derivative molecules for therapeutic treatment

Claim this profile

Follows are private to you and power your alerts

Updated · skyebioscience.com

Sector
Biotech
Headquarters
SAN DIEGO, CA
Founded
2011
Latest Form D
$40M, Mar 2024
Total capital
$167M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$167M
14 Form D · last Mar 2024
31 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $167M9th Form D$62.3M11th Form D$40M
20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $167M9th Form D$62.3M

Latest events

  • Private capital raisedForm D · SEC · 11th filing$40M
  • Private capital raisedForm D · SEC · 10th filing$50M
  • Private capital raisedForm D · SEC · 9th filing$62.3M
  • Private capital raisedForm D · SEC · 8th filing$2M
  • Private capital raisedForm D · SEC · 7th filing$2.4M
  • Private capital raisedForm D · SEC · 6th filing$2M
  • Private capital raisedForm D · SEC · 5th filing$1.2M
  • Private capital raisedForm D · SEC · 4th filing$500K
  • Private capital raisedForm D · SEC · 3rd filing$5M
  • Private capital raisedForm D · SEC · 2nd filing$625K
  • Private capital raisedForm D · SEC · 1st filing$725K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

3 records have no date or no amount, so they aren’t placed on the timeline.

Founders and team

From SEC Form D filings
  • Andrew SchwabDirectorNamed in SEC Form D filings
  • Annalisa JenkinsDirectorNamed in SEC Form D filings
  • Deborah CharychDirectorNamed in SEC Form D filings
  • Kaitlyn ArsenaultExecutive OfficerNamed in SEC Form D filings
  • Keith WardDirectorNamed in SEC Form D filings
  • Margaret DalesandroDirectorNamed in SEC Form D filings
Show all 9 people
  • Paul GraysonDirectorNamed in SEC Form D filings
  • Praveen TyleDirectorNamed in SEC Form D filings
  • Punit DhillonExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Monocacy Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
  • Fulcrum TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Erasca, Inc.Similar federal contract value in Biotech · null in contracts
  • LIGHT SWITCH BIO, LLCSimilar federal contract value in Biotech · null in contracts
  • Artiva BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Verastem, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .